MarketWatch
Real-time markets & breaking news
Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy
By Jaimy Lee
Read original article on MarketWatch
The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.
This story was originally published on MarketWatch. DennTech aggregates headlines from top crypto publications to keep traders informed.
Read full article on MarketWatch